FDA Approves First mRNA Flu Shot from Moderna The US Food and Drug Administration (FDA) has approved Moderna's mFlusiva, the first mRNA based flu shot in the country.
This approval marks a significant milestone in vaccine development, as it allows researchers to adapt quickly to emerging viral strains. mRNA vaccines have several advantages over traditional ones.
They can be manufactured in weeks, rather than months, which enables rapid response to new viral threats.